Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 April 2019

Abstract and Keywords

This chapter examines how, over the past two decades, there has been a rapid emergence of pharmacological treatment options for patients with generalized social anxiety disorder (GSAD). Results of treatment and neuroimaging studies suggest the involvement of serotonin, gamma-amino-butyric acid (GABA)/glutamate, and dopamine in GSAD. The literature clearly supports the use of SSRIs and the SNRI venlafaxine ER as first-line pharmacological agents in the treatment of GSAD; however, there is a paucity of data for patients who obtain a partial or nonresponse to first-line treatments as well as strategies to move GSAD individuals from response to remission. Exposure-based treatments are considered to be the gold standard treatment for specific phobias. There is a small literature on the use of pharmacological agents in specific phobias that does not support their use as the primary treatment modality.

Keywords: anxiety, anxiety treatment, pharmacotherapy, social anxiety, social phobia, treatment resistance

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.